Anticoagulation in Atrial Fibrillation with Chronic Kidney Disease

Introduction to Anticoagulant Choice

The American College of Cardiology recommends apixaban over warfarin for patients with atrial fibrillation and stage 3 chronic kidney disease (CKD) due to its superior safety profile and lower renal clearance 1, 2, 4.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, over warfarin for patients with CKD G1-G4 1.

Apixaban has the lowest renal clearance (25-27%) among all direct oral anticoagulants (DOACs), making it the safest option for patients with impaired kidney function 2, 3.
The 2019 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines support apixaban use in moderate-to-severe CKD with appropriate dose adjustments 4.

The standard dose of apixaban is 5 mg twice daily, unless the patient meets two or more of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, in which case the dose should be reduced to 2.5 mg twice daily 4, 5, 6.
Stage 3 CKD alone (creatinine clearance 30-59 mL/min) does not trigger dose reduction unless combined with other criteria 5, 6.

Renal function should be reassessed at least annually in all patients on apixaban, and more frequently (every 3-6 months) in patients with stage 3 CKD 1, 2, 6.
Drug interactions, such as strong P-glycoprotein and CYP3A4 inhibitors, should be avoided, and NSAIDs and COX-2 inhibitors should be used with caution due to the increased risk of bleeding and worsening renal function 2, 6.

If renal function declines to a creatinine clearance <30 mL/min, apixaban 2.5 mg twice daily may be considered with caution, or warfarin may be used as an alternative 6.
For perioperative management, apixaban should be held for 24-48 hours before low bleeding risk procedures and 48-96 hours before high bleeding risk procedures, depending on the patient's creatinine clearance 1.
The risk of bleeding, particularly gastrointestinal bleeding, should be monitored, and apixaban has been shown to have a 31% lower major bleeding risk compared to warfarin 6.